September #84 : Parent Trap - by Susan Gerhard

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

This Face has a Message for the World

Lines Composed in a Looking Glass

The Problem with Protease

Lipo: The Latest

Parent Trap

What's Life Worth?

ADA R.I.P.?

Wind Beneath Their Wings

Fuzzy Math:

Double Deal:

Getting Snippy

Creature Features

Clit Club

Con:

Safe Sucks:

Our Daily Med

Thymouse?

Run Interference

Look, Ma, No KS!

Warts Up, Doc?

Thai Clip:

Only Connect:

False Alarm:

Tribute: Linda Grinberg

Bayou Blues

Milestones:

Heroes

Mailbox

Back to Basics

Publisher's Letter



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

September 2002

Parent Trap

by Susan Gerhard

When doctors and parents disagree on HAART for kids with HIV, "when to start" goes to court

It's the stuff of summer movies: A father flees halfway across the world to keep his daughter safe from government authorities who he believes intend to kill her. Only in this case, the daughter is HIV positive, the father is an alternative health-care practitioner, and the authorities are police and child-welfare officers convinced they're saving the girl's life. The British family, whose names aren't being released, was extradited from Australia in May and returned to Britain, where the girl was made a ward of the court. Whether or not the 3-year-old will receive HAART -- a treatment choice her dad, a reflexologist, vehemently opposes -- was to be decided in a private office on May 10 not by a doctor, but by a High Court justice. (The decision was not made public.) The obvious question: With research on pediatric HIV treatment still in its infancy, is a judge even qualified to script an ending to this thriller?

The U.S. guidelines for pediatric HIV care are far from decisive. While they're clear that kids with symptoms should go on meds, they state that "when to initiate therapy for asymptomatic...children...is less certain." Sharon Nachman, MD, of the State University of New York at Stony Brook, who helped draft the recommendations, explained that they encourage docs to make the critical decision to treat or not case by case, depending on the child's CD4s and viral load and the likelihood of compliance. The calculations are complex: On the one hand, viral loads are typically high in babies born with HIV until age 2, and hitting early, say the guidelines, "could theoretically preserve immune function." On the other hand, liver function is barely developed at that stage, so med dosage must be extremely high, risking toxicities, and complete viral suppression is less common than in adults, risking drug resistance. On top of that, only a few HIV meds come in palatable cherry syrups; the rest are capsules or solutions that the under-5 set is likely to reject. All of this introduces the frightening prospect of a child burning through regimens and facing salvage therapy by age 8. Said Nachman, "I, like others, need to feel that the family is invested in the therapy before starting."

If the parents don't buy in, effective adherence is only a fantasy. In the case of the Brit tot, their disagreement with medical orthodoxy began early on. The girl's dad and mom, who has since died of AIDS, declined to give their newborn the standard preventive six weeks of AZT, and when the child was 4 months old, they left the country to avoid having her tested for HIV.

Pediatric HIV expert Andrew Wiznia, MD, of Jacobi Medical Center in the Bronx, said that HAART saves lives, noting that he's had to attend only one patient funeral in the past three years. The CDC guidelines report that the drugs reduced mortality from 5 percent in 1995 to 1 percent in 1997 for HIV positive kids with symptoms or immune damage. But the studies all compared HAART with dual or monotherapy, leaving parents with no data on survival for kids who delay treatment altogether.

The British case mirrors two others in the U.S. in which parents who disagreed with prevailing HIV-treatment tenets were taken to court. In Eugene, Oregon, Kathleen Tyson, who learned of her HIV status late in her pregnancy, lost custody of her child in 1998 for refusing AZT and breast-feeding him -- a high-risk activity. Though her breast milk and her child tested HIV negative, she was forced to follow doctor's orders, including six weeks of AZT for the infant, before he was allowed to come home.

In Bangor, Maine, HIV positive mother Valerie Emerson had obediently followed treatment guidelines for her daughter Tia, only to watch her die in 1997 while on AZT. When she then decided against treating her 4-year-old son, Nikolas, with HAART in '98, she had to go to court to win the right. In an unusual act of discretion, District Court Judge Douglas Clapp decided that pediatric HIV treatment was a "rapidly evolving art," and that "Maine is in no position to tell [Emerson] in the face of her unique experience that she is wrong...to wait for better and more reliable treatment methods."

Meanwhile, parents and docs are charged with the daunting task of weighing the benefits and risks of meds for these children on a scale that's constantly changing. "There is talk of an initiate therapy-vs.-wait protocol in the PACTG, but it will be a long time before data is available," said Wiznia. It may be that "hit early, hit hard" in babies will soon be as obsolete as monotherapy, and kids, like grownups, will be allowed to wait until their CD4s drop. The jury is still out on that question, but the courts -- where parents lose custody for being treatment conservatives -- are very much in session.




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.